Market Cap
US$800.5m
Last Updated
2020/06/05 02:11 UTC
Data Sources
Company Financials +
Executive Summary
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Limited growth with imperfect balance sheet.
Share Price & News
How has ImmunoGen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IMGN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-1.9%
IMGN
0.07%
US Biotechs
2.9%
US Market
1 Year Return
109.6%
IMGN
23.9%
US Biotechs
8.9%
US Market
Return vs Industry: IMGN exceeded the US Biotechs industry which returned 24.7% over the past year.
Return vs Market: IMGN exceeded the US Market which returned 9.2% over the past year.
Shareholder returns
| IMGN | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.9% | 0.07% | 2.9% |
| 30 Day | 14.5% | 4.8% | 10.6% |
| 90 Day | 9.5% | 10.5% | 5.1% |
| 1 Year | 109.6%109.6% | 25.1%23.9% | 11.4%8.9% |
| 3 Year | 4.6%4.6% | 32.9%28.5% | 34.3%25.4% |
| 5 Year | -67.7%-67.7% | -4.4%-10.0% | 60.7%42.7% |
Price Volatility Vs. Market
How volatile is ImmunoGen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
How Much Did ImmunoGen, Inc.'s (NASDAQ:IMGN) CEO Pocket Last Year?1 month ago | Simply Wall St
ImmunoGen, Inc. (NASDAQ:IMGN) Just Reported Earnings, And Analysts Cut Their Target Price1 month ago | Simply Wall St
Did Changing Sentiment Drive ImmunoGen's (NASDAQ:IMGN) Share Price Down A Worrying 59%?Valuation
Is ImmunoGen undervalued compared to its fair value and its price relative to the market?
Share Price vs. Fair Value
Below Fair Value: IMGN ($4.59) is trading above our estimate of fair value ($4.29)
Significantly Below Fair Value: IMGN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IMGN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: IMGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMGN has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
Next Steps
Future Growth
How is ImmunoGen forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
25.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMGN's revenue (35.6% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: IMGN's revenue (35.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMGN's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has ImmunoGen performed over the past 5 years?
-8.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMGN is currently unprofitable.
Growing Profit Margin: IMGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMGN is unprofitable, and losses have increased over the past 5 years at a rate of -8.3% per year.
Accelerating Growth: Unable to compare IMGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: IMGN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is ImmunoGen's financial position?
Financial Position Analysis
Short Term Liabilities: IMGN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: IMGN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: IMGN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: IMGN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMGN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMGN has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 7.6% each year.
Next Steps
Dividend
What is ImmunoGen's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.1yrs
Average management tenure
CEO
Mark Enyedy (55yo)
4.08yrs
Tenure
US$3,917,560
Compensation
Mr. Mark J. Enyedy has been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 and had been its Interim Principal Financial Officer since November 26, 2018. Mr. Enyedy is an In ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD3.92M) is about average for companies of similar size in the US market ($USD3.13M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.08yrs | US$3.92m | 0.25% $2.0m | |
| Senior Vice President of Technical Operations | no data | US$1.57m | 0.043% $347.1k | |
| Senior VP & Chief Medical Officer | 5.17yrs | US$1.81m | 0.056% $450.2k | |
| VP of Finance & Chief Accounting Officer | no data | no data | 0.012% $98.1k | |
| Senior Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| VP & Chief Human Resources Officer | 1.92yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality | no data | no data | 0.040% $323.6k | |
| Senior VP & Chief Business Officer | no data | no data | no data | |
| Secretary | no data | no data | no data |
4.1yrs
Average Tenure
56.5yo
Average Age
Experienced Management: IMGN's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.08yrs | US$3.92m | 0.25% $2.0m | |
| Independent Chairman | 10.58yrs | US$124.77k | no data | |
| Independent Director | 8.42yrs | US$88.77k | 0.0057% $45.9k | |
| Independent Director | 8.42yrs | US$98.77k | no data | |
| Independent Director | 12.58yrs | US$91.77k | no data | |
| Independent Director | 2.42yrs | US$81.77k | no data | |
| Independent Director | 8.58yrs | US$88.77k | 0.031% $247.0k |
8.4yrs
Average Tenure
63yo
Average Age
Experienced Board: IMGN's board of directors are considered experienced (8.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.6%.
Top Shareholders
Company Information
ImmunoGen, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: ImmunoGen, Inc.
- Ticker: IMGN
- Exchange: NasdaqGS
- Founded: 1980
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$800.523m
- Shares outstanding: 174.41m
- Website: https://www.immunogen.com
Number of Employees
Location
- ImmunoGen, Inc.
- 830 Winter Street
- Waltham
- Massachusetts
- 2451
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IMGN | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Nov 1989 |
| IMU | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 1989 |
| IMU | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Nov 1989 |
| IMGN * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Nov 1989 |
Biography
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/05 02:11 |
| End of Day Share Price | 2020/06/04 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.